Molecular aspects of the congenital and acquired Long QT Syndrome: Clinical implications

Journal of Molecular and Cellular Cardiology

Volumn 44, Issue 4, 2008, Pages 633-646

  Saenen, J B ^a,b   Vrints, C J ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Pharmacology and Physiology   (Belgium)

Author keywords

Acquired; Arrhythmia; CACNA1c; Congenital; Genotype; hERG; Ion channel; KCNE1; KCNE2; KCNJ2; KCNQ1; Long QT Syndrome; Phenotype; SCN5A; Sudden cardiac death; Torsade de pointes

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOPRENALINE; NICORANDIL;

CLINICAL FEATURE; DEFIBRILLATOR; ELECTROCARDIOGRAPHY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HUMAN; LIFESTYLE MODIFICATION; LONG QT SYNDROME; MOLECULAR MECHANICS; PACEMAKER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TORSADE DES POINTES;

GENOTYPE; HUMANS; LONG QT SYNDROME; PHENOTYPE;

EID: 43049112043     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.01.006     Document Type: Review

References (84)

1. Zipes D.P. Epidemiology and mechanisms of sudden cardiac death. Can J Cardiol 21 Suppl A (May 2005) 37-40
2. Myerburg R.J., Kessler K.M., and Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 119 12 (Dec 15 1993) 1187-1197
3. Valdes-Dapena M. Sudden unexplained infant death, 1970 through 1975: an evolution in understanding. Pathol Annu 12 Pt 1 (1977) 117-145
4. Naeye R.L. The sudden infant death syndrome: a review of recent advances. Arch Pathol Lab Med 101 4 (Apr 1977) 165-167
5. Roden D.M. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 21 5 (May 1998) 1029-1034
6. Jervell A., and Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 54 1 (Jul 1957) 59-68
7. Romano C., Gemme G., and Pongiglione R. [Rare cardiac arrythmias of the pediatric age. II. Syncopal attacks due to paroxysmal ventricular fibrillation. (presentation of 1st case in Italian pediatric literature)]. Clin Pediatr (Bologna) 45 (Sep 1963) 656-683
8. Ward O.C. A new familial cardiac syndrome in children. J Ir Med Assoc 54 (Apr 1964) 103-106
9. Fraser G.R., Froggatt P., and Murphy T. Genetical aspects of the cardio-auditory syndrome of Jervell and Lange-Nielsen (congenital deafness and electrocardiographic abnormalities). Ann Hum Genet 28 (Nov 1964) 133-157
10. Dessertenne F. [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss 59 2 (Feb 1966) 263-272
11. Akar F.G., Yan G.X., Antzelevitch C., and Rosenbaum D.S. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 105 10 (Mar 12 2002) 1247-1253
12. Yan G.X., Wu Y., Liu T., Wang J., Marinchak R.A., and Kowey P.R. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103 23 (Jun 12 2001) 2851-2856
13. Antzelevitch C., Shimizu W., Yan G.X., Sicouri S., Weissenburger J., Nesterenko V.V., et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 10 8 (Aug 1999) 1124-1152
14. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47 2 (Aug 2000) 219-233
15. Abbott G.W., Sesti F., Splawski I., Buck M.E., Lehmann M.H., Timothy KW, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97 2 (Apr 16 1999) 175-187
16. + channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly-activating delayed rectifier current. J Biol Chem 273 (1998) 27231-27235
17. Mohler P.J., Schott J.J., Gramolini A.O., Dilly K.W., Guatimosim S., duBell W.H., et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421 6923 (Feb 6 2003) 634-639
18. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 350 10 (Mar 4 2004) 1013-1022
19. Saenen J.B., Paulussen A.D., Jongbloed R.J., Marcelis C.L., Gilissen R.A., Aerssens J., et al. A single hERG mutation underlying a spectrum of acquired and congenital long QT syndrome phenotypes. J Mol Cell Cardiol 43 1 (Jul 2007) 63-72
20. Nerbonne J.M., and Kass R.S. Molecular physiology of cardiac repolarization. Physiol Rev 85 4 (Oct 2005) 1205-1253
21. Delisle B.P., Anson B.D., Rajamani S., and January C.T. Biology of cardiac arrhythmias: ion channel protein trafficking. Circ Res 94 11 (Jun 11 2004) 1418-1428
22. Trudeau M.C., Warmke J.W., Ganetzky B., and Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269 (1995) 92-95
23. Ks potassium channel. Nature 384 (1996) 80-83
24. Tawil R., Ptacek L.J., Pavlakis S.G., DeVivo D.C., Penn A.S., Ozdemir C., et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 35 3 (Mar 1994) 326-330
25. Splawski I., Timothy K.W., Decher N., Kumar P., Sachse F.B., Beggs A.H., et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A 102 23 (Jun 7 2005) 8089-8096
26. Bennett P.B., Yazawa K., Makita N., and George Jr. A.L. Molecular mechanism for an inherited cardiac arrhythmia. Nature 376 6542 (Aug 24 1995) 683-685
27. Vatta M., Ackerman M.J., Ye B., Makielski J.C., Ughanze E.E., Taylor E.W., et al. Mutant Caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation (Oct 23 2006)
28. Mohler P.J. Ankyrins and human disease: what the electrophysiologist should know. J Cardiovasc Electrophysiol 17 10 (Oct 2006) 1153-1159
29. Medeiros-Domingo A., Kaku T., Tester D.J., Iturralde-Torres P., Itty A., Ye B., et al. SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 116 2 (Jul 10 2007) 134-142
30. Splawski I., Shen J., Timothy K.W., Lehmann M.H., Priori S., Robinson J.L., et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 102 10 (Sep 5 2000) 1178-1185
31. Silva J., and Rudy Y. Subunit interaction determines IKs participation in cardiac repolarization and repolarization reserve. Circulation 112 10 (Sep 6 2005) 1384-1391
32. Rudy Y. Modelling and imaging cardiac repolarization abnormalities. J Intern Med 259 1 (Jan 2006) 91-106
33. Roden D.M. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 259 1 (Jan 2006) 59-69
34. Jones E.M., Roti Roti E.C., Wang J., Delfosse S.A., and Robertson G.A. Cardiac IKr channels minimally comprise hERG 1a and 1b subunits. J Biol Chem 279 43 (Oct 22 2004) 44690-44694
35. Kr channel. J Gen Physiol 107 (1996) 611-619
36. Anderson C.L., Delisle B.P., Anson B.D., Kilby J.A., Will M.L., Tester D.J., et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113 3 (Jan 24 2006) 365-373
37. McPhee J.C., Ragsdale D.S., Scheuer T., and Catterall W.A. A critical role for the S4-S5 intracellular loop in domain IV of the sodium channel alpha-subunit in fast inactivation. J Biol Chem 273 2 (Jan 9 1998) 1121-1129
38. Schwartz P.J. The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med 259 1 (Jan 2006) 39-47
39. Tristani-Firouzi M., Jensen J.L., Donaldson M.R., Sansone V., Meola G., Hahn A., et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 110 3 (Aug 2002) 381-388
40. Wang D., Papp A.C., Binkley P.F., Johnson J.A., and Sadee W. Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet Genomics 16 10 (Oct 2006) 735-745
41. Yang P., Kanki H., Drolet B., Yang T., Wei J., Viswanathan P.C., et al. Allelic variants in long-QT disease genes in patients with drug- associated torsades de pointes. Circulation 105 16 (Apr 23 2002) 1943-1948
42. Fernandez D., Ghanta A., Kauffman G.W., and Sanguinetti M.C. Physicochemical features of the HERG channel drug binding site. J Biol Chem 279 11 (Mar 12 2004) 10120-10127
43. Mitcheson J.S., Chen J., Lin M., Culberson C., and Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97 22 (Oct 24 2000) 12329-12333
44. Labro A.J., Raes A.L., Bellens I., Ottschytsch N., and Snyders D.J. Gating of Shaker-type channels requires the flexibility of S6 caused by prolines. J Biol Chem 278 50 (Sep 17 2003) 50724-50731
45. Paulussen A.D., Gilissen R.A., Armstrong M., Doevendans P.A., Verhasselt P., Smeets H.J., et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 82 3 (Mar 2004) 182-188
46. Sanguinetti M.C., and Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 440 7083 (Mar 23 2006) 463-469
47. Kuryshev Y.A., Ficker E., Wang L., Hawryluk P., Dennis A.T., Wible B.A., et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312 1 (Jan 2005) 316-323
48. Paulussen A., Raes A., Matthijs G., Snyders D.J., Cohen N., and Aerssens J. A novel mutation (T65P) in the PAS domain of the human potassium channel HERG results in the long QT syndrome by trafficking deficiency. J Biol Chem 277 50 (Dec 13 2002) 48610-48616
49. Ingelman-Sundberg M., Sim S.C., Gomez A., and Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116 3 (Dec 2007) 496-526
50. Brink P.A., Crotti L., Corfield V., Goosen A., Durrheim G., Hedley P., et al. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation 112 17 (Oct 25 2005) 2602-2610
51. Priori S.G., Napolitano C., and Schwartz P.J. Low penetrance in the long-QT syndrome: clinical impact. Circulation 99 4 (Feb 2 1999) 529-533
52. Desmyttere S., Bonduelle M., De Wolf D., Liebaers I., and Lissens W. A case of term mors in utero in a chromosome 11p linked long QT syndrome family. Genet Couns 5 3 (1994) 289-295
53. Ramakers C., Vos M.A., Doevendans P.A., Schoenmakers M., Wu Y.S., Scicchitano S., et al. Coordinated down-regulation of KCNQ1 and KCNE1 expression contributes to reduction of I(Ks) in canine hypertrophied hearts. Cardiovasc Res 57 2 (Feb 2003) 486-496
54. Crotti L., Lundquist A.L., Insolia R., Pedrazzini M., Ferrandi C., De Ferrari G.M., et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation 112 9 (Aug 30 2005) 1251-1258
55. Ackerman M.J., Tester D.J., Jones G.S., Will M.L., Burrow C.R., and Curran M.E. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 78 12 (Dec 2003) 1479-1487
56. Moss A.J., Zareba W., Kaufman E.S., Gartman E., Peterson D.R., Benhorin J., et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 105 7 (Feb 19 2002) 794-799
57. Donger C., Denjoy I., Berthet M., Neyroud N., Cruaud C., Bennaceur M., et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 96 9 (Nov 4 1997) 2778-2781
58. Kagan A., Yu Z., Fishman G.I., and McDonald T.V. The dominant negative LQT2 mutation A561V reduces wild-type HERG expression. J Biol Chem 275 15 (Apr 14 2000) 11241-11248
59. Gong Q., Zhang L., Vincent G.M., Horne B.D., and Zhou Z. Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome. Circulation 116 1 (Jul 3 2007) 17-24
60. Westenskow P., Splawski I., Timothy K.W., Keating M.T., and Sanguinetti M.C. Compound mutations: a common cause of severe long-QT syndrome. Circulation 109 15 (Apr 20 2004) 1834-1841
61. Lee M.P., Hu R.J., Johnson L.A., and Feinberg A.P. Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. Nat Genet 15 2 (Feb 1997) 181-185
62. Schwartz P.J., Moss A.J., Vincent G.M., and Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation 88 2 (Aug 1993) 782-784
63. Swan H., Viitasalo M., Piippo K., Laitinen P., Kontula K., and Toivonen L. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J Am Coll Cardiol 34 3 (Sep 1999) 823-829
64. Zipes D.P., Camm A.J., Borggrefe M., Buxton A.E., Chaitman B., Fromer M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 10 (Sep 5 2006) e385-e484
65. Napolitano C., Priori S.G., Schwartz P.J., Bloise R., Ronchetti E., Nastoli J., et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 294 23 (Dec 21 2005) 2975-2980
66. Schwartz P.J., Priori S.G., Spazzolini C., Moss A.J., Vincent G.M., Napolitano C., et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103 1 (Jan 2 2001) 89-95
67. Hobbs J.B., Peterson D.R., Moss A.J., McNitt S., Zareba W., Goldenberg I., et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 296 10 (Sep 13 2006) 1249-1254
68. Sauer A.J., Moss A.J., McNitt S., Peterson D.R., Zareba W., Robinson J.L., et al. Long QT syndrome in adults. J Am Coll Cardiol 49 3 (Jan 23 2007) 329-337
69. Locati E.H., Zareba W., Moss A.J., Schwartz P.J., Vincent G.M., Lehmann M.H., et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 97 22 (Jun 9 1998) 2237-2244
70. Abi-Gerges N., Philp K., Pollard C., Wakefield I., Hammond T.G., and Valentin J.P. Sex differences in ventricular repolarization: from cardiac electrophysiology to torsades de pointes. Fundam Clin Pharmacol 18 2 (Apr 2004) 139-151
71. Pham T.V., Sosunov E.A., Gainullin R.Z., Danilo Jr. P., and Rosen M.R. Impact of sex and gonadal steroids on prolongation of ventricular repolarization and arrhythmias induced by I(K)-blocking drugs. Circulation 103 17 (May 1 2001) 2207-2212
72. Choi G., Kopplin L.J., Tester D.J., Will M.L., Haglund C.M., and Ackerman M.J. Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes. Circulation 110 15 (Oct 12 2004) 2119-2124
73. Wilde A.A., Jongbloed R.J., Doevendans P.A., Duren D.R., Hauer R.N., van Langen I.M., et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 33 2 (Feb 1999) 327-332
74. Priori S.G., Schwartz P.J., Napolitano C., Bloise R., Ronchetti E., Grillo M., et al. Risk stratification in the long-QT syndrome. N Engl J Med 348 19 (May 8 2003) 1866-1874
75. Moss A.J., Zareba W., Hall W.J., Schwartz P.J., Crampton R.S., Benhorin J., et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101 6 (Feb 15 2000) 616-623
76. Priori S.G., Napolitano C., Schwartz P.J., Grillo M., Bloise R., Ronchetti E., et al. Association of long QT Syndrome loci and cardiac events among patients treated with β-blockers. JAMA 292 11 (Sep 15 2004) 1341-1344
77. Karjalainen J., Viitasalo M., Manttari M., and Manninen V. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 23 7 (Jun 1994) 1547-1553
78. Malik M., Acar B., Gang Y., Yap Y.G., Hnatkova K., and Camm A.J. QT dispersion does not represent electrocardiographic interlead heterogeneity of ventricular repolarization. J Cardiovasc Electrophysiol 11 8 (Aug 2000) 835-843
79. Lubinski A., Kornacewicz-Jach Z., Wnuk-Wojnar A.M., Adamus J., Kempa M., Krolak T., et al. The terminal portion of the T wave: a new electrocardiographic marker of risk of ventricular arrhythmias. Pacing Clin Electrophysiol 23 11 Pt 2 (Nov 2000) 1957-1959
80. Thomsen M.B., Verduyn S.C., Stengl M., Beekman J.D., de Pater G., van Opstal J., et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110 16 (Oct 19 2004) 2453-2459
81. Zhang L., Timothy K.W., Vincent G.M., Lehmann M.H., Fox J., Giuli L.C., et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 102 23 (Dec 5 2000) 2849-2855
82. Zhang L., Benson D.W., Tristani-Firouzi M., Ptacek L.J., Tawil R., Schwartz P.J., et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 111 21 (May 31 2005) 2720-2726
83. Shimizu W., and Antzelevitch C. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 102 6 (Aug 8 2000) 706-712
84. Hansen R.S., Diness T.G., Christ T., Wettwer E., Ravens U., Olesen S.P., et al. Biophysical Characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-Bromo-2-(1H-tetrazol-5-yl)-phenyl)-N′-(3′-trifluoromet hylphenyl)urea]. Mol Pharmacol 70 4 (Oct 2006) 1319-1329